JSKN016HC / Alphamab - LARVOL DELTA

JSKN016:…Expected Milestones in 2026 (from Q2 2026) (Alphamab Press Release) - "(i) Pre‑IND communication for the combination study of JSKN016 in CDK4/6‑pretreated HR‑positive BC will be completed in the United States; (ii) The phase I clinical study of the subcutaneous formulation of JSKN016 in Australia will complete the first patient dosing; (iii) Results of JSKN016 monotherapy in TNBC and HR‑positive BC will be presented; (iv) Results of JSKN016 monotherapy and combination therapy in NSCLC will be presented; (v) Phase III clinical study of JSKN016 in combination therapy as first‑line treatment for NSCLC will be initiated."

Clinical data • New P3 trial • Preclinical • Trial status • Hormone Receptor Positive Breast Cancer • Non Small Cell Lung Cancer • Triple Negative Breast Cancer